Ambulatory electrocardiographic monitoring was used to assess the anti- ischemic effects of amlodipine in a subset of 56 patients enrolled in a 14- week withdrawal study; amlodipine therapy resulted in a marked decrease in the overall mean number of ischemic events and the average number of transient ischemic episodes (p <0.005). Amlodipine substantially reduced the number of ischemic events among all patients during the single-blind phase, with further significant reductions recorded among patients who remained on amlodipine during double-blind therapy, but the number of ischemic events increased almost to baseline levels in patients switched to placebo during double-blind therapy (p = 0.01 by analysis of variance).
